Authors: Dr Daniel Mazzoni, Resident Medical Officer, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia; Dr Nicholas Lucarelli, Resident Medical Officer, Eastern Health, Melbourne, VIC, Australia. DermNet Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. May 2020.
Taxanes are a class of chemotherapeutic agents used in the treatment of some cancers [1]. They were first derived from the bark of yew trees.
Two of the most common taxanes used in clinical practice are docetaxel and paclitaxel [2].
How do taxanes work?
Taxanes are antineoplastic drugs that inhibitmitosis by interfering with microtubule formation during cell division. By targeting cells with a high turnover, they can slow the growth of solid organ tumours [2].
What are the clinical uses for taxanes?
Taxanes are used in an adjuvant setting or as a primary treatment of cancer [2]. They are administered intravenously every week (paclitaxel) or every three weeks (docetaxel).
They are used for the primary treatment of [2]:
Breast cancer
Castration-resistant prostate cancer
Non-small cell lung cancer
Gastric cancer
Pancreatic cancer
Head and neck cancer
Cervical cancer
Ovarian cancer
Urothelial cancer.
They can also be used in conjunction with other chemotherapy agents.
What are the adverse effects of taxanes?
Like other cytotoxic agents, the side effects of taxanes largely affect organ systems with high mitotic turnover rates.
The most common adverse effects are [2,3]:
Fatigue
Body aches
Loss of appetite.
Other adverse effects include [2,3]:
Nausea, vomiting, and diarrhoea
Peripheral sensory neuropathy
Neutropenia
Cutaneous effects.
What are the cutaneous adverse effects of taxanes?
Adverse cutaneous reactions occur in most patients on taxane therapy. They arise more frequently with docetaxel than with paclitaxel [2]. Taxanes affect hair, nails, mucosa, and skin. Most adverse effects are of mild to moderate severity and are usually dose-dependent (depending on the frequency of dosing, the dose intensity, and the cumulative dose). Symptoms usually resolve spontaneously after cessation of taxane therapy [2,4].
Dorsal hand-foot syndrome due to chemotherapy
Nail changes due to chemotherapy
Eczematousdermatitis on male undergoing chemotherapy treatment
Hair loss from taxanes
Taxanes cause acute reversible alopecia, also known as chemotherapy-induced alopecia [2].
Diffuse hair loss occurs in approximately 60% of patients, usually after the first chemotherapy cycle.
Taxanes result in thinning of scalp hair and may affect other hair-bearing areas with higher doses or prolonged therapy.
Hair growth tends to recover 3–6 months after therapy, but a few cases of permanent or irreversible alopecia due to taxanes have been reported.
Scalp cooling systems such as cool caps have been shown to prevent the alopecia in a number of trials [4].
Haemorrhagiconycholysis and subungualhaematoma/abscess appear to be unique to the taxanes.
Nail disease due to taxanes is generally cumulative. It tends to resolve within a few weeks after discontinuing taxanes.
Skin cooling systems such as frozen gloves have been shown to reduce the adverse effects on the nails [4]. Avoidance of trauma to the hands and nails, and the use of hand moisturisers are recommended. The use of nail lacquer also seems to be helpful, suggesting photo-sensitivity may play a role in the development of some of the nail effects [6].
Mucositis caused by taxanes
Mucositis due to taxanes is common, particularly stomatitis. Dysgeusia may also occur, typically within the first week of therapy [2].
Adverse effects of taxanes in the skin
Skin toxicities due to taxanes are broad with various manifestations as described below [2].
Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344(8932):1267-72. doi:10.1016/s0140-6736(94)90754-4.PubMed
Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26(5):427–43. doi:10.1684/ejd.2016.2833.Journal
Markman M. Managing taxane toxicities. Support Care Cancer. 2003;11(3):144–7. doi:10.1007/s00520-002-0405-9.PubMed
Marks DH, Qureshi A, Friedman A. Evaluation of prevention interventions for taxane-induced dermatologic adverse events: a systematic review. JAMA Dermatol. 2018;154(12):1465-72. doi:10.1001/jamadermatol.2018.3465.PubMed
Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181–9. doi:10.1016/S1470-2045(14)71133-7.PubMed
Alshari O, Aleshawi A, Al Sharie AH, et al. The effect of nail lacquer on taxane-induced nail changes in women with breast cancer. Breast Cancer (Auckl). 2020;14:1178223420929702. doi:10.1177/1178223420929702. PubMed
Picard M, Castells MC. Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol. 2015;49(2):177–91. doi:10.1007/s12016-014-8416-0.PubMed
Marchetti MA, Noland MM, Dillon PM, et al. Taxane associated subacute cutaneous lupus erythematosus 2013; 19: 192–59. PubMed
Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link?. Clin Exp Dermatol. 2004;29(4):360–2. doi:10.1111/j.1365-2230.2004.01519.x.PubMed
Aydogan I, Kavak A, Parlak AH, Alper M, Annakkaya AN, Erbas M. Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol. 2005;19(3):345–7. doi:10.1111/j.1468-3083.2005.01088.x.PubMed